Axillary Pathologic Complete Response After Neoadjuvant Syst
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
This systematic review and meta-analysis can help estimate axillary treatment response in the neoadjuvant setting and thus select patients for more or less invasive axillary procedures.

The objective of this study was to provide pooled data of all studies in the neoadjuvant setting on axillary pCR rates for different breast cancer subtypes in patients with initially clinically node-positive disease.

The electronic databases Embase and PubMed were used to conduct a systematic literature search on July 16, 2020. Studies in the neoadjuvant therapy setting were identified regarding axillary pCR for different breast cancer subtypes in patients with initially clinically node-positive disease.

This pooled analysis included 33 unique studies with 57?531 unique patients and showed the following axillary pCR rates for each of the 7 reported subtypes in decreasing order: 60% for hormone receptor (HR)–negative/ERBB2 (formerly HER2)–positive, 59% for ERBB2-positive (HR-negative or HR-positive), 48% for triple-negative, 45% for HR-positive/ERBB2-positive, 35% for luminal B, 18% for HR-positive/ERBB2-negative, and 13% for luminal A breast cancer. No major differences were found in the axillary pCR rates per subtype by analyzing separately the studies of patients with and without pathologically proven clinically node-positive disease before neoadjuvant systemic therapy.

The HR-negative/ERBB2-positive subtype was associated with the highest axillary pCR rate. These data may help estimate axillary treatment response in the neoadjuvant setting and thus select patients for more or less invasive axillary procedures.

JAMA Surgery
Source: https://jamanetwork.com/journals/jamasurgery/article-abstract/2778930
Like
Comment
Share